| Regulatory T cells (T reg cells) are a small subset of immune cells that are dedicated to curbing excessive immune activation and maintaining immune homeostasis. Accordingly, deficiencies in T reg cell development or function result in uncontrolled immune responses and tissue destruction and can lead to inflammatory disorders such as graft-versus-host disease, transplant rejection and autoimmune diseases. As T reg cells deploy more than a dozen molecular mechanisms to suppress immune responses, they have potential as multifaceted adaptable smart therapeutics for treating inflammatory disorders. Indeed, early-phase clinical trials of T reg cell therapy have shown feasibility, tolerability and potential efficacy in these disease settings. In the meantime, progress in the development of chimeric antigen receptors and in genome editing (including the application of CRISPR-Cas9) over the past two decades has facilitated the genetic optimization of primary T cell therapy for cancer. These technologies are now being used to enhance the specificity and functionality of T reg cells. In this Review , we describe the key advances and prospects in designing and implementing T reg cell-based therapy in autoimmunity and transplantation.
The adaptive immune system has evolved to recognize and destroy a virtually infinite variety of pathogens while remaining unresponsive towards self-tissues; this state is known as immune tolerance. Immune tolerance is maintained by a multilayered, interconnected and redundant array of dominant and recessive mechanisms, ensuring that immune responses are regulated in an effective and timely manner 1,2 . Recessive immune tolerance mechanisms are cell intrinsic and include the deletion of selfreactive immune cells, rendering them non-functional (that is, subject to anergy) and increasing the number of inhibitory receptors on immune cells to increase their activation threshold. By contrast, dominant immune tolerance mechanisms are cell extrinsic and are carried out by subsets of specialized immune cells that actively suppress the activation, expansion and function of other immune cells, thereby regulating the intensity and the duration of immune responses.
Autoimmune disorders arise from defects in immune tolerance and affect more than 50 million individuals in the United States alone and more than 4% of the world population. Progress in treating individuals with these diseases has been slow owing to the complex mechanisms underlying the balance between immune reactivity and immune tolerance. Although small-molecule and biologic treatments can alleviate symptoms, they are often non-specific, require long-term administration (and thus long-term exposure to the toxic effects associated with them) and do not account for variability in underlying disease pathogenesis and drug responses. For instance, the mainstay treatment for severe systemic lupus erythematosus, an autoimmune disorder caused by autoreactive B cells, is steroids, which non-specifically suppress inflammation. Living drugs, such as regulatory T cells (T reg cells), may have greater specificity and more complex therapeutic benefits than conventional immunosuppressive drugs (such as steroids and ciclosporin), biologics (such as rituximab and belimumab), antimetabolites (such as azathioprine and methotrexate) and alkylating agents (such as cyclophosphamide), amongst others, and could potentially cure disease by restoring immune tolerance.
T cell-based antigen-specific immune tolerance was first postulated in 1970 (ref. 1 ). However, T reg cells were not identified as the main cell type responsible for this phenomenon until the 1990s 2 . T reg cells constitute 5% of circulating CD4 + T cells and can be identified by the lineage marker forkhead box protein P3 (FOXP3). Mutations in the gene encoding FOXP3 (a transcription factor), as well as in genes encoding other mol ecules that modulate T reg cell function, such as the surface receptors cytotoxic T lymphocyte protein 4 (CTLA-4) and CD25 (also known as IL-2 receptor subunit-α, part of the trimeric high-affinity IL-2 receptor) and Anergy Peripheral mechanism for tolerizing T cells in which they are blocked at the G1 phase of the cell cycle and unable to proliferate. the transcription factor signal transducer and activator of transcription 5 (STAT5), lead to the development of severe autoimmune polyendocrine syndromes; the best known example of these syndromes is immunodysregulation polyendocrinopathy enteropathy X-linked syndrome 3 . Moreover, T reg cells can become unstable, losing FOXP3 expression and immunosuppressive function, converting into effector T cells (T eff cells) under extreme inflammatory conditions 4, 5 . The inability of T reg cells to produce IL-2 while expressing high levels of CD25 is a cardinal feature of T reg cells. Thus, in the absence of IL-2 produced by other cell subtypes, or signalling by its receptor, there is a decrease in the number and functional activity of the T reg cells, leading to inflammation and autoimmunity 6, 7 . Expression of CD127 (also known as IL-7 receptor subunit-α) is inversely correlated with the expression of FOXP3 and the suppressive function of human T reg cells, and is currently used in conjunction with CD25 as a phenotypic marker in the purification of T reg cells, defined as CD4 + CD25 + CD127 low T cells 8, 9 . However, the best indicator of a stable T reg cell lineage is demethylation of the T reg cell-specific demethylated region (TSDR), an evolutionarily conserved noncoding regulatory sequence in the FOXP3 locus; demethylation of the TSDR ensures high, stable levels of FOXP3 (ref. 10 ).
The dominance and durability of T reg cell-mediated immune tolerance is underscored by two main features: bystander suppression and infectious tolerance. During bystander suppression, which was first described by Weiner and colleagues 11 in 1991, T reg cells activated by one antigen suppress immune responses against other antigens. During infectious tolerance, a term coined by Gershon and Kondo 12 in 1971 and expanded by Waldmann and colleagues 13 in 1993, suppressive capacity is transferred from one cell population to another. This process is thought to occur mainly via the production of inhibitory cytokines by T reg cells; these cytokines block dendritic cell (DC) maturation and migration, creating a local tolerogenic environment in which T eff cells undergo apoptosis and naive T cells are converted to induced T reg cells. Molecularly, T reg cells act through pleiotropic mechanisms, depending on their target cells and whether they are in lymphoid organs or in non-lymphoid tissues 14 . Furthermore, studies in mice and humans show that T reg cells become specialized, converting into cells with type 1 T helper cell (T H 1 cell)-like, type 2 T helper cell (T H 2 cell)-like and IL-17-producing T helper cell (T H 17 cell)like phenotypes, characterized by distinct patterns of chemokine receptor, cytokine and transcription factor expression [15] [16] [17] [18] . Genetic deletion experiments in vivo indicate that, by expressing chemokine receptors similar to those on specific T helper cell subsets, specialized T reg cells can more efficiently suppress their targets 19 . In addition to suppressing immune responses, murine T reg cells promote tissue repair following viral infection 19 .
Of note, CD4 + FOXP3 + T reg cells are not the only immuno suppressive cells. Other cell types with immunosuppressive functions include CD8 + T reg cells, IL-10producing type 1 T reg cells (T R 1 cells), transforming growth factor-β (TGFβ)-producing CD4 + T H 3 cells, regulatory γδ T cells, regulatory B cells (B reg cells), myeloid-derived suppressor cells, immunosuppressive plasmocytes, regulatory invariant natural killer (NK) T cells and even subsets of innate lymphoid cells (BoX 1). Yet, to date, FOXP3 + T reg cells are the only known cell line age arising in the thymus that is exclusively dedicated to inducing and maintaining immune tolerance. Moreover, almost all ongoing clinical trials using cell therapy to induce immune tolerance use CD4 + FOXP3 + T reg cells. Hence, in this Review, we focus on strategies to engineer CD4 + FOXP3 + T reg cells as the next generation of living drugs for treatment of autoimmune and inflammatory diseases. First, we critically assess the current status of T reg cell therapy, including challenges in the isolation and manufacture of T reg cells, finding the best disease indication and the potential crosstalk of T reg cell therapy with other immunosuppressive treatments. Then we discuss the prospects of tailoring T reg cell specificity and function using genome editing and synthetic biology.
Fundamentals of T reg cells as a therapy T reg cells are an attractive therapeutic candidate for restoring immune tolerance in autoimmune and autoinflammatory diseases, and thus for reducing or replacing immunosuppressive drugs. T reg cells are also being considered as a therapy for inducing tolerance to allogeneic cells and tissues upon the transplantation of haematopoietic stem cells and solid organs. As of July 2019, 51 clinical trials using T reg cells had been registered in ClinicalTrials.gov, of which six have been completed (NCT01634217, NCT00602693, NCT01210664, NCT02166177, NCT02244801 and NCT02129881), five terminated (NCT02428309, NCT00725062, NCT01050764, NCT00376519 and NCT01818479), four suspended (NCT02494492, NCT02991898, NCT02526329 and NCT03773328) and two withdrawn (NCT02118311 and NCT01163201) (fIG. 1) . Overall, these studies demonstrate the feasibility and safety of T reg cell infusion, although their small size, in general, limited the opportunity to assess efficacy. The relatively high rate of prematurely terminated, suspended or withdrawn trials mostly reflects challenges in manufacturing T reg cells and in selecting and recruiting patients, as discussed later in this Review.
T reg cells as living drugs
In traditional pharmacology, a drug is characterized according to its pharmacodynamics, that is, its effect in the body (such as its on-target and off-target interactions), and its pharmacokinetics, that is, the effect of the body on its absorption, distribution and metabolism. Several properties are key to successfully using T reg cells as living drugs, and these can be summed up as the four S's: suppression, survival, stability and specificity (fIG. 2).
T reg cell-meditated immunosuppression.
The main goal of T reg cell therapy is to induce or re-establish immune tolerance; this goal requires the suppressive function of T reg cells, which is influenced by factors such as their activation status, their cytokine milieu, the availability of antigen and the affinity of the T cell receptors (TCRs) for the recognized antigens. Although continuous TCR signalling is required for the repressive function of
Systemic lupus erythematosus
A group of chronic autoimmune disorders defined by inflammation affecting various connective tissues in various organs, including the skin, joints, kidney, lung, nervous system or haematopoietic system.
Autoimmune polyendocrine syndromes
A group of diseases characterized by loss of tolerance and inflammation in endocrine glands, including the thyroid, parathyroid and adrenal glands or the pancreas. They are frequently associated with alopecia, vitiligo, coeliac disease and autoimmune gastritis.
Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome
Specific form of an inherited autoimmune polyendocrine syndrome characterized by a mutation or mutations in the master transcription factor forkhead box protein P3 gene (FOXP3), leading to regulatory T cell dysfunction.
Type 1 T helper cell
(T H 1 cell). A type of CD4 + T helper cell expressing TBeT as a key transcription factor and defined by its ability to preferentially secrete interferonγ and induce CD8 + T cell and macrophage activation.
Type 2 T helper cell
(T H 2 cell). A type of CD4 + T helper cell expressing GATA3 as a key transcription factor and defined by its ability to preferentially secrete Il-4, IL-5 and IL-13 and promote B cell expansion and antibody class switching.
T reg cells 20 , and T reg cells are highly sensitive to activation by the recognized antigen 21 , the impact of TCR affinity on T reg cell-mediated suppression is unclear. Some studies suggest that T reg cells expressing high-affinity TCRs have a more potent suppressive function than T reg cells expressing low-affinity TCRs 22,23 , whereas others have found that T reg cells expressing TCRs with affinities that differ by several orders of magnitude have a similar suppressive function 24 .
There are several mechanisms of T reg cell-mediated suppression, including IL-2 deprivation (wherein T reg cells act as an IL-2 sink, reducing the primary growth and survival factor for T eff cells), the secretion of inhibitory cytokines (such as IL-10 and TGFβ) and the acquisition of costimulatory molecules from antigen-presenting cells (APCs) via high-affinity binding to CTLA-4 (ref. 25 ).
Currently, the suppressive function of human T reg cells is primarily quantified by measuring the degree to which they inhibit T eff cell proliferation in vitro or prevent graft-versus-host disease (GvHD) in humanized mice. Additional in vitro assays include measuring T reg cellmediated suppression of mixed lymphocyte reactions, which depends on the interaction of CTLA-4 on T reg cells with DCs 26 , and the inhibition of inflammatory cytokine production by T eff cells 27 .
Different subsets of T reg cells specialize in suppressing specific T helper cell subsets: T H 1 cell-like T reg cells, which have a similar gene signature to T H 1 cells, are most effective in inhibiting T H 1 cells, T H 2 cell-like T reg cells are most effective in inhibiting T H 2 cells, and so on 14, 16 . Furthermore, studies in mice have demonstrated that the expression of chemokine receptors on T reg cell subsets Box 1 | The increasing diversity of immunosuppressive cell types A successful immune response entails the eradication of the pathogen and the timed contraction of activated immune cell populations to avoid excessive tissue damage. The best understood subsets of immunoregulatory cells that, in addition to CD4 + FoXP3 + regulatory T cells (T reg cells), play a role in suppressing immune responses and maintaining immune homeostasis are briefly summarized here.
Type 1 T reg cells
Inducible type 1 T reg cells (T R 1 cells) are CD4 + FoXP3 − T cells that secrete the immunosuppressive molecule IL-10. Some T R 1 cells also express granzyme B and can kill myeloid cells 213 . T R 1 cells are enriched by the simultaneous expression of CD49b and lymphocyte activation gene 3 protein (LAG3) 214 . In vitro, T R 1 cell expansion protocols use vitamin D 3 , dexamethasone 215 or IL-10-producing antigen-presenting cells to generate antigen-specific T R 1 cells 216 . In 2012, in the first open-label uncontrolled, multicentre, single-infusion dose-escalation phase I/IIa clinical trial using T R 1 cells, ovalbumin-specific T R 1 cells were injected into 20 patients with refractory Crohnʼs disease; the injection was well tolerated and showed dose-related efficacy 217 . A multicentre phase II trial using T R 1 cells was completed in 2016 (NCT02327221; results not yet available). T R 1 cell-based cell therapy has also been successful in haematological diseases, preventing graft-versus-host disease and improving immune reconstitution 218 .
CD8 + T reg cells
In 1970 one group established that T cells could suppress antibody responses 1 , and hypothesized that suppressor T cells existed 219 . T cells expressing CD8α (Ly-2 at the time) and CD8β (Ly-3), but not CD4 (Ly-1), were later found to have suppressive functions 220 . CD8 + T reg cells were thus the first suppressor cells to be identified. CD8 + T reg cells share markers with activated conventional CD8 + T cells, making it difficult to isolate them or dissect their function. Nevertheless, human CD8 + FoXP3 + CD45RC low T reg cells are potent suppressive cells in graft-versus-host disease and solid organ transplantation 221 , and CD8 + FoXP3 + CD25 + TNFR2 + T reg cells are suppressive in patients with type 1 diabetes treated with teplizumab, a humanized anti-CD3 antibody 222 . FoXP3 expression may allow the identification of bona fide human CD8 + T reg cells. In mice, the transcription factor HELIOS is required for the stability of both CD4 + and CD8αα + T reg cells in a proinflammatory milieu 223 . CD8αα + T reg cells reside in the intestine, recognize the nonclassical major histocompatibility complex molecule Qa1 (HLA-E in humans) and protect against CD4 + T cell-mediated colitis 224, 225 . CD8 + T reg cells may primarily suppress activated T cells by killing them directly or by secreting inhibitory cytokines.
Type 3 T helper cells
Transforming growth factorβ (TGFβ)-producing type 3 T helper cells (T H 3) were identified when SJL mice, which are susceptible to experimental autoimmune encephalomyelitis (EAE), were fed myelin basic protein (MBP), and MBP-specific CD4 + T cell clones were isolated from mesenteric lymph nodes 226 . These clones secreted low levels of interferonγ (a hallmark of T H 1 cells), IL-4 (a hallmark of T H 2 cells) and IL-10 and high levels of TGFβ. Adoptive transfer of these T cell clones suppressed EAE in mice immunized with MBP in a TGFβ-dependent manner. The study authors named these mucosal regulatory cells T H 3 cells 226 . T H 3 cell-derived TGFβ can prevent and reverse autoimmune encephalomyelitis by inducing T reg cell differentiation 227 . T H 3 cells may have an important role in controlling autoimmunity and allergy in humans.
Regulatory B cells
Regulatory B cells (B reg cells) secrete anti-inflammatory cytokines, mainly IL-10, and suppress the proliferation of lymphocytes, including effector T cells 228 . B cell-mediated tolerance was originally hypothesized in the 1970s 229 , but it was not until 1996, when the genetic ablation of B cells was shown to decrease the frequency of spontaneous recovery from eAe, that a regulatory role for B reg cells was proposed 230 . B cells in mice that recovered from eAe were found to secrete IL-10 in response to self-antigen, and the genetic ablation of IL-10 in B cells prevented spontaneous recovery from EAE 231 . Inflammation seems to trigger the induction of B reg cells through the production of IL-10 by suppressive cells at the inflamed site 232 . Accordingly, individuals with chronic inflammation and autoimmunity display deficiencies in the number and function of suppressive cells circulating and at the inflamed site 233 . Importantly, B reg cells skew T cell differentiation towards T reg cells 234,235 and promote T reg cell expansion 236, 237 , suggesting that they act by promoting T reg cell activity.
Mixed lymphocyte reactions
In vitro tests consisting of mixing different subsets of T cells together in the presence of antigen-presenting cells.
NATuRe RevIews | DRug DisCoveRy R e v i e w s volume 18 | oCToBeR 2019 | 751 must mimic the expression of chemokine receptors on T helper cell subsets for specialized T reg cells to preferentially migrate and suppress specific T helper cell-driven immune responses 14 . The approach to maximize the suppressive function of T reg cells will likely need to be tailored for each therapeutic application.
T reg cell survival. Unlike small molecules and biologics, living cells can change their identity or undergo apoptosis in response to the levels of oxygen, nutrients and signalling molecules in their new environment. Indeed, T reg cells infused in humans and in non-human primates rapidly (that is, within 2 weeks) decreased in number [28] [29] [30] . However, using deuterium to label infused T reg cells, a later study showed that a marked percentage of infused T reg cells are detected in some patients up to 1 year following infusion 31 ; these data indicate that better techniques, such as the use of gene-modified cells, are needed to assess, and increase, the survival of human T reg cells in patients. Circulating T reg cells constantly require exogenous IL-2 for their survival, as they do not produce this cytokine themselves 6 . Nevertheless, tissueresident T reg cells can become IL-2 independent, relying instead on IL-7 and IL-33 for their survival and stability 32, 33 . New insights into the metabolic requirements and signalling circuitry of T reg cells may yield strategies to enhance T reg cell survival.
T reg cell stability. FOXP3 expression is central to the T reg cell lineage. Loss of FOXP3 expression and/or ablation of the TSDR in the FOXP3 locus results in loss of T reg cell identity and systemic autoimmunity 3, 34 . In response to proinflammatory or otherwise inhospitable conditions, T reg cells transdifferentiate into T eff cells (also known as 'ex-T reg cells'), including pathogenic T H 1 cells, T H 2 cells and T H 17 cells 4, 5, 35 . Thus, once administered, antigenspecific T reg cells targeting a specific tissue could convert into pathogenic cells with the same specificity and further exacerbate tissue damage. Strategies to increase T reg cell stability include the ectopic expression of the transcription factors FOXP3, HELIOS and BACH2 (refS [36] [37] [38] ), which activate or repress gene transcription, or of a constitutively active form of STAT5 (ref. 6 ), as well as the genetic ablation of PRKCQ (encoding protein kinase C-θ (PKCθ); PKCθ is found in the immune synapse and controls early T cell activation events critical for T reg cell stability) 39, 40 , STUB1 (encoding the E3 ubiquitin-protein ligase carboxy terminus of Hsp70-interacting protein (CHIP)) or CCAR2 (encoding deleted in breast cancer gene 1 protein (DBC1)); CHIP and DBC1 promote FOXP3 degradation 41, 42 .
T reg cell specificity. Most clinical trials conducted to date using T reg cell therapy have used ex vivo expanded polyclonal T reg cells. Yet, antigen-specific T reg cells are superior to their polyclonal counterparts in their migration to, and persistence in, the target tissue, and in their execution of a local immunosuppressive response 43, 44 . These properties of antigen-specific T reg cells will allow, compared with polyclonal T reg cells, the use of fewer cells, greatly reducing the risk of inducing unwanted, widespread, nonspecific immunosuppression. In addition to isolating and expanding endogenous antigen-specific T reg cells, it is also possible to create T reg cells with a desired specificity by TCR gene transfer 23, [45] [46] [47] . The use of artificial immune receptors, such as chimeric antigen receptors (CARs), to redirect T reg cell specificity towards pathogenic T cells or the affected tissue has expanded this approach 48, 49 .
Manufacturing T reg cells for therapy
Manufacturing T reg cells involves choosing the source from which T reg cells should be isolated as well as the methods for purifying and expanding T reg cells, product specification and release criteria. Detailed information on protocols for producing T reg cells is often only partially provided in the literature. A 'minimum information about T regulatory cells' document has been generated in a first but critical step towards process reproducibility and standardization 50 . ). The large circle shows the overall number of registered trials, divided into coloured segments that represent the proportion of these clinical trials with their status defined as not yet recruiting (blue), recruiting (green), active not recruiting (yellow), terminated or completed (pink), withdrawn or suspended (light grey) and unknown (dark grey). Unknown status corresponds to studies, the last known status of which was recruiting, not yet recruiting, or active, not recruiting, but that have passed their completion date but have not had their status verified within the past 2 years (http:// clinicaltrials.gov). Small circles are categorized by indication: hematopoietic stem cell transplantation or graft-versus-host disease, solid organ transplantation and autoimmune disease.
www.nature.com/nrd
Sources of human T reg cells. Several sources of human T reg cells have been explored. Peripheral blood is the most accessible, and often the only, option for autologous applications. Umbilical cord blood (UCB) has been successfully tested in GvHD using partially human leukocyte antigen (HLA)-matched T reg cells from non-autologous UCB donors 30, 51, 52 . T reg cells can also be isolated from discarded thymuses removed during paediatric cardiac surgery. Approximately 300 × 10 6 CD4 + CD25 + T reg cells can be isolated from thymuses from one donor 53 , which is equivalent to the number of T reg cells in the entire blood volume of an adult donor. Thus, paediatric thymuses may be an attractive source of non-autologous T reg cells, even though this source is yet to be tested in clinical trials or multiple preclinical models 53 .
Methods of purifying T reg cells.
If T reg cells are to be expanded in vitro before infusion, the starting T reg cell population must be of high purity. This requirement is because T reg cells proliferate slowly when compared with conventional CD4 + T cells and CD8 + T cells. Minor conventional CD4 + T cell and CD8 + T cell contaminants at the outset of the expansion can allow cells other than T reg cells to overtake the culture, preventing the generation of a pure T reg cell product. The markers initially used to isolate T reg cells were CD4 and CD25. Although expression of these markers is sufficient for isolating T reg cells from UCB, it was not sufficient for isolating T reg cells from adult peripheral blood containing activated antigen-experienced conventional T cells expressing CD25 (ref. 54 ). Selection of the T cells on the basis of low CD127 expression greatly increased T reg cell purity and recovery from peripheral blood and lymphoid tissue 8, 9 . Additional T reg cell markers are likely to result from efforts aimed at pinpointing the molecular signatures of bona fide T reg cells 55,56 .
Two methods have been used to purify T reg cells: magnetic-activated cell sorting (MACS) and fluorescenceactivated cell sorting (FACS). Although MACS-based approaches are good manufacturing practice (GMP) compliant and can process billions of cells simultaneously, they are imprecise and often result in T reg cells with insufficient purity, a low rate of T reg cell recovery or both. By contrast, FACS allows the precise identification of T reg cells through the use of multiple markers, ensuring high purity and high recovery; however, the process is slow and limits the number of cells that can be processed to ~10 9 peripheral blood mononuclear cells (PBMCs) per day, consequently limiting the dose that can be manufactured. In addition, FACS instrumentation, for example, FACSAria (Becton Dickinson), is typically not GMP compliant owing to open air processing and unexchangeable parts that are in contact with cells. Exceptions include the new FX500 fluidics cell sorter (Sony) and the three-laser MACSQuant Tyto cell sorter (Miltenyi Biotec), closed on-chip sorting systems with exchangeable parts used to enrich and purify the final population. Nonetheless, both MACS and FACS are currently being used to manufacture T reg cells for use in the clinic; the regulatory environment of the country and financial resources of the investigators often dictate which method is chosen.
Methods of expanding T reg cells.
Most T reg cell therapies aim to increase, albeit transiently, the number of T reg cells to reset the inflammation-prone state of the recipient. This inhibitory effect is estimated to require an infusion of millions to billions of T reg cells 57 and, thus, requires the expansion of T reg cells before infusion. So far, T reg cells used in clinical trials have been mostly expanded by polyclonal stimulation; that is, anti-CD3 and anti-CD28 beads 30 T cells and to maintain high FOXP3 expression during T reg cell expansion, many centres culture the cells in the presence of rapamycin, an inhibitor of the mechanistic target of rapamycin (mTOR). T reg cells are less sensitive to phosphatidylinositol 3-OH kinase (PI3K) activity (an upstream kinase in the signalling pathway that activates mTOR) than conventional T cells, making them markedly less sensitive to the anti-proliferative effect of rapamycin than T eff cells [61] [62] [63] . Including rapamycin in cell cultures is especially important when T reg cells are purified by MACS as it helps to compensate for the considerably reduced initial purity of the T reg cells. Importantly, however, rapamycin also suppresses the expansion of T reg cells, leading to longer culture durations that require repeated stimulation with anti-CD3 and anti-CD28 beads, and sometimes with artificial APCs, to produce sufficient doses of T reg cells. Our laboratories have shown that rapamycin is not needed when T reg cells are purified by FACS with selection for CD4 + CD25 + CD127 low T reg cells 58 . Antigen-specific approaches for expanding T reg cell populations are being developed and used. These approaches include the manufacture of clinical grade human alloantigenreactive T reg cells following expansion in the presence of donor-derived stimulated B cells, which selectively increases the pool of alloantigen-reactive T reg cells that is naturally present in the blood 64, 65 . Of note, DCs 66 and K562 cell-based artificial APCs 67 have also been used to expand human T reg cells ex vivo. As T reg cells proliferate poorly in vitro, most protocols for expanding T reg cells rely on the use of strong stimulants to drive cell proliferation and on high concentrations of IL-2 to sustain T reg cell expansion 65 . Yet, considerable variability in the proliferative potential of T reg cells has been observed during ex vivo expansion 68 . This variability may relate to the activation state of the cells, which is reported to be affected by the age of the T reg cell donor, as well as the donor's immunological experiences, inflammatory conditions and current medications. For example, CD45RA-expressing naive T reg cells are in a resting state when isolated, yet readily expand upon in vitro stimulation and maintain their T reg cell lineage after expansion more efficiently than CD45RA − T reg cells 58,69,70 . Among CD45RA − T reg cells, recently activated effector T reg cells negative for CCchemokine receptor type 7 (CCR7) have the least potential for expansion and are the most likely to lose expression of FOXP3 (ref. 71 ). Consistent with these observations, UCB-derived T reg cells are mainly naive, bestowing them with a growth advantage over their peripheral blood counterparts 72 . Unexpectedly, T reg cells isolated from infant thymuses, although mostly naive, do not proliferate as effectively as T reg cells from adult peripheral blood 53 .
Product specification and release criteria for T reg cells.
Most centres conducting T reg cell therapy trials agree that the expanded T reg cell product should remain CD4 + CD25 + FOXP3 high CD127 low , and these markers are widely used to define product identity. Activated conventional human T cells also show a transient increase in FOXP3 expression in response to TCR-CD28 signals, limiting the reliability of this marker alone for the identification of expanded human T reg cells and explaining why lineage-committed T reg cells are identified by demethylation at TSDRs. In activated conventional T cells that transiently upregulate FOXP3, the TSDR remains methylated 73, 74 . The ongoing development of validated and quantitative standardized assays for measuring TSDR demethylation in lymphocytes, such as the one performed by Epiontis 75 , could soon allow the routine inclusion of this important criterion for T reg cell product release.
Lessons from T reg cell therapy trials Taming transplant rejection
Thus far, excellent safety profiles have been consistently shown in patients receiving T reg cells 14 . T reg cell therapy was first applied in GvHD, supported by striking efficacy data from preclinical models in the early years of the first decade of this century 76, 77 . In 2009, a team in Gdansk, Poland, published the first report of T reg cell therapy in humans. In this study, ex vivo expanded CD4 + CD25 + CD127 low T reg cells were infused into one patient with acute (grade IV) GvHD and two patients with chronic GvHD. T reg cells alleviated symptoms, and pharmacological immunosuppression could be reduced in chronic, but not acute, GvHD 59 . Subsequent studies provided encouraging results regarding the use of T reg cells to prevent and treat acute and chronic GvHD 30,51,78-80 , although two clinical trials have been withdrawn (NCT01163201, NCT02118311). These studies were halted for reasons other than safety, including logistics, trial design and replacement with a new study.
Alloantigen-reactive T reg cells can attenuate donorreactive T cells in preclinical models of transplantation, providing robust evidence to justify their evaluation in clinical trials 64, 81, 82 . As a result, they are being tested in several phase I studies in kidney and liver transplantation 60,83,84 (fIG. 1). Overall, T reg cell infusions have been safe and well tolerated and, although manufacturing the cells in the context of chronic immunosuppressive treatments remains challenging, these studies provide enough safety data to advance T reg cell therapy to phase II trials. Data from these trials, which will include efficacy, will be unveiled in the coming years.
Autoimmune and autoinflammatory disease
There is much interest in using T reg cells to treat autoimmune diseases, particularly patients with type 1 diabetes (T1D). Strong preclinical data were obtained in the non-obese diabetic (NOD) mouse model 43 . A single infusion of ex vivo expanded islet-specific T reg cells prevented autoimmunity and restored sustained selftolerance in mice with recent diabetes onset. The natural pool of T reg cells in NOD mice is numerically normal, preferentially expands in the pancreatic lymph nodes of prediabetic mice and migrates to inflamed islets. Yet, T reg cells fail to control islet destruction owing to a survival disadvantage in chronically inflamed islets 85 . Moreover, NOD T eff cells are more resistant to T reg cellmediated suppression than their B6 mouse counterparts 86 . The first clinical trial testing polyclonal T reg cell therapy in T1D showed T reg cell administration to be safe K562 cell-based artificial APCs K562 cells are an immortalized human leukocyte antigen (HLA)-deficient cell line initially isolated from a chronic myelogenous leukaemia. Artificial antigen-presenting cells (APCs) are K562 cells that have been gene edited to express CD80 and/or CD86 and specific HLA alleles to function as APCs.
www.nature.com/nrd and well tolerated, and the children into whom T reg cells had been infused had markedly higher C-peptide levels and lower insulin requirements than children in the untreated group 28 . In a second phase I clinical trial conducted in the United States, ex vivo expanded poly clonal T reg cells were infused into 14 patients with T1D in doses ranging from 5 × 10 6 to 2.6 × 10 9 cells. Infusions were well tolerated, and C-peptide levels in most patients remained stable for 1 year, although efficacy could not be conclusively shown. Notably, cell pharmacokinetic analysis of T reg cells labelled with deuterium during ex vivo expansion showed that a small but visible percentage of the infused T reg cells persisted in peripheral blood for at least 1 year without evidence of deuterium-positive T eff cells; this finding demonstrates that the T reg cells remained phenotypically stable after infusion 31 . Nonetheless, a phase II clinical trial (NCT02691247) performed by Caladrius Biosciences, in which 113 newly diagnosed (that is, less than 100 days since T1D diagnosis) adolescents with T1D into whom autologous ex vivo polyclonally expanded T reg cells had been infused failed to show that T reg cell infusion led to preservation of C-peptide production 1 year after the start of treatment (see Related links). The trial is ongoing but these negative results are in agreement with the finding in preclinical models that antigen-specific, and not polyclonal, T reg cells are required to reverse T1D as the frequency of islet-specific T reg cells in blood is extremely low. One strategy is to artificially redirect peripheral blood T reg cells to specific antigens (see later).
Two smaller studies assessing the use of T reg cells in the treatment of autoimmune and autoinflammatory diseases have also been reported. The first study focused on one patient with systemic lupus erythematosus and active skin disease who received 1 × 10 8 autologous T reg cells expanded by polyclonal stimulation 87 . The T reg cells migrated into the affected areas of the skin and markedly attenuated the activity of the interferon-γ (IFNγ) pathway while enhancing the activity of the IL-17 pathway 87 . Of note, IL-17 may be involved in barrier homeostasis. Thus, a shift from IFNγ to IL-17 may lead to reduced skin inflammation and tissue repair. In the second study, three patients with amyotrophic lateral sclerosis, who received eight consecutive infusions of T reg cells while undergoing IL-2 therapy, showed reduced disease progression 88 . In short, the field is steadily moving forward, with several phase I clinical trials aiming to test T reg cell therapy in autoimmune hepatitis (NCT02704338), pemphigus vulgaris (NCT03239470), inflammatory bowel disease (NCT03185000), Guillain-Barré syndrome (NCT03773328) and Alzheimer disease (NCT03865017).
Co-medication and T reg cell therapy IL-2 therapy and T reg cells.
In the 1990s, and counterintuitively at the time, mice deficient in the crucial T cell growth factor IL-2 displayed uncontrolled T cell activation and succumbed to widespread autoimmunity 89 . Later experiments revealed that IL-2 is required for the development, homeostasis and suppressive function of T reg cells 90 , explaining this observation and suggesting that IL-2 could be used to expand T reg cells in vivo in patients with autoimmune disease 6 . Although other immune cells -such as conventional T cells, NK cells and some subsets of innate lymphoid cells -express the IL-2 receptor, as T reg cells constitutively express CD25 (a component of the high-affinity IL-2 receptor), lowdose IL-2 should preferentially affect T reg cells 91 . Thus far, the best evidence that this phenomenon occurs in humans comes from an uncontrolled phase I/IIa clinical trial in patients with hepatitis C-mediated vasculitis that is resistant to treatment with IFNα and the antiviral ribavirin 92 . Low-dose IL-2 treatment had efficacy in eight out of ten patients, as judged by an increase in T reg cell frequency and a concomitant decrease in the proportion of marginal zone B cells 92 . A concurrent study revealed that daily low-dose IL-2 treatment increased T reg cell numbers and alleviated chronic GvHD symptoms in 12 of the 23 patients treated 93 . Finally, an uncontrolled trial using a low dose of IL-2 to treat patients with systemic lupus erythematosus also showed efficacy, with the expansion of T reg cells, T follicular helper cells and T H 17 cells, but not of T H 1 cells or T H 2 cells, along with decreased disease activity 94 .
Currently, nine trials are actively testing the efficacy of low-dose IL-2 treatment for several autoimmune diseases. The TRANSREG study goes even further, comparing, in a multicentre, uncontrolled, open-label study, 14 autoimmune diseases (NCT01988506). In T1D, low-dose IL-2 therapy is safe and augments T reg cell numbers; however, the numbers of NK cells and eosinophils were also increased, and efficacy is yet to be demonstrated [95] [96] [97] . Hence, IL-2 therapy could be combined with T reg cell therapy to increase efficacy, and three clinical trials are currently testing this hypothesis in the treatment of T1D (NCT02772679), steroid refractory chronic GvHD (NCT01937468) and amyotrophic lateral sclerosis (NCT03241784). Future approaches may include the use of IL-2-anti-IL-2 complexes that selectively expand T reg cells 98 . Alternatively, engineering an orthogonal IL-2 molecule specific to an orthogonal IL-2 receptor is feasible and would allow the selective expansion and survival of the infused engineered cells 99 .
Crosstalk with immunosuppressive regimens. Patients with autoimmune disease are often treated with several immunosuppressive drugs, including corticosteroids (such as prednisone), antimetabolites (such as methotrexate, azathioprine, mycophenolate mofetil and leflunomide), alkylating agents (such as cyclophosphamide), blocking monoclonal antibodies that target cytokines or their receptors (such as anti-tumour necrosis factor (TNF), anti-IL-1β, anti-IL-4 receptor subunit-α (which simultaneously inhibits the IL-4 and IL-13 pathways), anti-IL-5, anti-IL-6 and anti-IL-17), abatacept (which blocks CD80 and CD86 in APCs), and B cell-depleting antibodies (such as rituximab and belimumab). In the setting of transplantation, the interactions of different immunosuppressive drugs (for example, ciclosporin, rapamycin, anti-CD25 and thymoglobulin) with T reg cells need also to be evaluated, as reviewed elsewhere 100 . Immunosuppressive drugs may impact the number, expansion and function of T reg cells. If fewer T reg cells can be isolated and expanded from patients with autoimmune disease and transplant C-peptide Short polypeptide connecting the A chain of proinsulin to the B chain. After packaging in vesicles in pancreatic beta cells, C-peptide is removed from proinsulin, leaving the A chain and the B chain linked by a disulfide bridge. Blood C-peptide levels are used to monitor endogenous insulin expression in patients with diabetes.
Amyotrophic lateral sclerosis
Neurodegenerative disorder characterized by the progressive loss of motor neurons, causing muscle weakness, atrophy and eventually death.
Pemphigus vulgaris
Group of skin disorders characterized by the formation of blisters induced by autoantibodies targeting intercellular adhesion molecules on keratinocytes.
Guillain-Barré syndrome
Immune-mediated polyneuropathy, usually started after an infection, sharing cross-reactive epitopes with peripheral nerves (myelin or axonal membrane).
Alzheimer's disease
Neurogenerative disorder leading to progressive dementia associated with the accumulation of amyloidβ plaques in nervous cells of the central nervous system.
Marginal zone
High-transit area constituted by B cells, macrophages, dendritic cells and granulocytes, interposed between lymphoid tissues and the circulation, serving as a sentinel for blood-borne antigens.
NATuRe RevIews | DRug DisCoveRy recipients compared with healthy individuals, the minimum number of T reg cells required for product release, a typical hurdle in trials for T reg cell therapy in transplantation, may not be achieved 101 . Furthermore, the dosage of these treatments can vary widely during disease treatment, likely with variable effects on the T reg cell compartment. Encouraging preliminary results obtained from patients who underwent allogeneic kidney transplantation suggest that dialysis, immunosuppression and acute rejection episodes affect T reg cell maturation, resulting in a reduced percentage of mature T reg cells in these patients, but do not preclude ex vivo T reg cell expansion and the generation of a final T reg cell product with therapeutic properties 102 . Future research will shed light on this potential limitation as we gather data on the unwarranted interactions between immunosuppressive drug regimens and infused T reg cells.
Engineering T reg cell specificity T reg cells could potentially be manipulated to restore immune tolerance in the treatment of autoimmunity. T reg cells must migrate to appropriate sites and respond to their cognate antigen to effectively suppress immune responses. Studies in transgenic NOD mice genetically engineered to express the BDC2.5 diabetogenic TCR revealed that relatively small numbers of antigen-specific T reg cells, but not of polyclonal T reg cells, are sufficient to prevent and even reverse T1D 43 . Strikingly, in a B6 mouse model where insulitis and autoimmune diabetes were induced by expression of the proinflammatory cytokine TNF in islets, as few as 2,000 T reg cells isolated from the pancreatic draining lymph node could prevent diabetes 103 . These seminal studies established the importance of using antigen-specific T reg cells for therapy. Yet, only minute numbers of antigen-specific T reg cells relevant for a given condition are found in peripheral blood. Moreover, most antigen-specific T reg cells reside in tissues, making them difficult to isolate and their cognate antigens laborious to identify. These obstacles have fuelled interest in devising strategies to artificially direct T reg cells to a desired target (fIG. 3) .
Currently, engineered TCRs and CARs are the main receptors employed to impart T reg cell specificity. TCRs have lower affinity than CARs yet can recognize just one molecule per target cell 104 , whereas cells must have at least 100 target molecules for CARs to recognize them 105 . However, CAR targets tend to be moderately to highly expressed surface proteins. Thus, the difference in affinity between TCRs and CARs is compensated for by different expression levels of the ligands on target tissues. CARs are not subject to HLA restriction or dependent on a co-receptor, but whether the high affinity and downstream signalling of CARs are ideal for T reg cell function is unclear. The relative advantages and disadvantages of each receptor continue to be explored (TABLe 1) .
Ig-TCR chimeric receptor T cells reported 238
CAR T cells developed (firstgeneration CAR) 146 T reg cells suppress T eff cell activation in vitro 240 CAR with CD28 signalling drives robust CAR T cell expansion (secondgeneration CAR) 142 Ex vivo expanded antigen-specific T reg cells suppress T1D in NOD mice 43 
Large-scale expansion of human T reg cells ex vivo 250
Mouse TNP CAR T reg cells ameliorate colitis 152
CD19 CAR T cells eradicate B cell-lineage cells 251
First T reg cell therapy clinical trial for autoimmunity (T1D treated) 28 Human HLA-A2 CAR T reg cells prevent GvHD in mice 48 Human FVIII BAR T reg cells suppress FVIII-specific B cells 165 TCRs can redirect cytotoxic T cells 129 T-body chimeric receptor T cells reported 239 T reg cell transfer prevents autoimmunity in athymic mice 2 Identification of human T reg cells [241] [242] [243] [244] [245] [246] FOXP3 programmes T reg cell development and function [247] [248] [249] MBP-IA s -CD3ζ T reg cells recognize MBP-specific T cells and cure EAE in mice 49, 150 TCR-redirected mouse T reg cells suppress arthritis 131 CARs with two costimulatory domains reported (thirdgeneration CAR) 148 Human CEA CAR T reg cells suppress the death of CEA + tumours 156 First T reg cell therapy case reported (GvHD treated) 59 First T reg cell therapy clinical trial (GvHD treated) 30 Infused T reg cells persist for up to 1 year in patients with T1D 31 FDA approves Kymriah (Novartis) and Yescarta (Kite; a Gilead company) as CD19 CAR T cell therapies for leukaemia First T reg cell therapy pilot study for kidney transplantation 84 1986 1987 1989 1991 1995 1998 
HLA restriction
The presentation of a peptide by a specific human leukocyte antigen (HLA) to a T cell's receptor.
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Targeting TCRs to engineer T reg cells
The right TCR for a T reg cell. Perhaps the most straightforward way to redirect T reg cell specificity is to engineer a TCR recognizing a peptide of interest in the target tissue (fIG. 4) . The TCR is a heterodimer comprising an α-chain and a β-chain, each of which is composed of a variable region (VDJ) and a constant region. Each T cell expresses a unique TCR, owing to stochastic V(D)J recombination, which can generate up to 1 × 10 61 different TCR sequences in humans 106 ; detailed amino acid sequences of each individual region of many TCRs can be found in the IMGT database. Although most T cells with strong reactivity against self-peptide-major histocompatibility complex (MHC) class II complexes are clonally depleted in the thymus (an example of recessive immune tolerance), a subset of these cells acquire FOXP3 expression when the CNS2 enhancer in the first intron of the FOXP3 gene is demethylated 107, 108 . Thus, the TCR repertoire of thymically derived T reg cells is distinct from that of T eff cells, which have been selected for weak peptide-bound MHC-TCR interactions. Autoimmune regulator (AIRE), a transcriptional regulator driving tissue-specific antigen expression in the thymus, promotes T reg cell development by skewing autoreactive T cells towards a T reg cell phenotype 109, 110 . Still, some autoreactive T eff cells escape clonal deletion and they may share a common pool of self-reactive TCRs with T reg cells 111 . Distinct T reg cell TCRs can be specific to nonoverlapping peptides derived from the self-antigen that is targeted by autoantibodies, suggesting that T reg cells recognize only a few proteins deemed most susceptible to autoimmune recognition 112 .
As peptides from any protein (including intracellular proteins) can potentially be bound by MHC and recognized by the TCR, TCRs can be isolated or designed to recognize an almost infinite number of targets. Another advantage of the TCR is that the peptides it recognizes can be derived from proteins that are posttranslationally modified. Post-translational modification by oxidation 113 , deamidation 114 , citrullination 115 or phosphorylation 116 generates unique epitopes that typically circumvent central T cell deletion 117, 118 . Hybrid peptides (that is, products of the fusion of the amino terminus of one peptide to the carboxy terminus of another peptide by a peptide bond) have also been uncovered as important self epitopes 119, 120 .
Importantly, how TCRs can be engineered to impart T reg cell specificity may be different depending on whether T reg cells function primarily in lymphoid organs to restore immune tolerance or in tissues to suppress autoinflammation or induce tissue repair. In the mouse, continuous, steady-state TCR stimulation in lymphoid organs mediates suppression 20,121 , whereas in tissues that lack TCR stimulation and have low levels of IL-2, CD44 hi CD62L low CCR7 low T reg cells depend mainly on costimulation through inducible T cell costimulator (ICOS) for their maintenance 71, 122 . Additional signals that are important for the maintenance of tissue-resident murine T reg cells have been identified; T reg cells in adipose tissue rely on IL-33 (ref. 33 ), whereas memory T reg cells in the skin require IL-7 for survival 32 .
In inflammatory conditions, such as in murine autoimmune diabetes, T reg cells specific to islet-derived antigens clonally expand in inflamed islets but not in the spleen or lymph nodes 123 . T reg cells with high-affinity or low-affinity TCRs can be found in islets, and evidence supports the hypothesis that these T reg cell subsets have complementary roles in immune homeostasis 22 . Highaffinity T reg cells expressed high levels of suppressive molecules (namely IL-10, LAG3 and TIGIT), whereas low-affinity T reg cells expressed amphiregulin, a key factor in tissue repair 22 . Furthermore, T reg cell subsets charac terized by distinct cytokine profiles and transcription factor dependencies have been shown to feature TCR signalling of differing strengths 124 .
TCR immunosequencing as a route to engineering TCRs.
Progress in engineering TCRs will also depend on advances in TCR immunosequencing, at the single-cell level, and thus in predicting which peptides they recognize. High-throughput immunosequencing of the TCRα and TCRβ chains of CD4 + T cells, CD8 + T cells and T reg cells, in pancreatic tissues and blood, have uncovered a population of pancreas antigen-specific T cells selectively in the pancreatic islet tissue 125 . The local accumulation of these T cells suggests that they are reactive to islet antigens, making their TCRs potential candidates for redirecting T reg cells to peptides selectively expressed in the pancreas. However, knowledge of the sequence of both TCRα and TCRβ and of how they are paired to form heterodimers in a single T cell is needed to reconstitute TCR specificity. The cost of single-cell paired TCR NATuRe RevIews | DRug DisCoveRy sequencing technology is rapidly decreasing, permitting the routine use of this approach for characterizing TCR repertoires on various T cell subsets, including T eff cells and T reg cells. Additionally, a high-throughput method to pair TCRα and TCRβ genes without the need for singlecell technologies has been reported 126 . These new technologies will help rigorously define the TCR repertoire of T reg cells and, eventually, of autoimmune T cells, which can be used to engineer T cells for therapeutic purposes (fIG. 4) . However, predicting the epitope specificity of TCRs will be key, and several algorithms can now cluster TCR sequences on the basis of conserved motifs and complementarity-determining regions 127, 128 .
As had been previously shown with conventional T cells 129 , introducing a TCR from another antigenspecific T cell to T reg cells can effectively redirect them towards a known antigen specificity. In one example, T reg cells were transduced with TCRs that conferred them with specificity for a transplant antigen. Specifically, a TCR specific for a peptide derived from an MHC class I molecule (H-2K d from the BALB/c strain) presented by an MHC class II molecule (H-2A b from the B6 strain) was transduced into B6 T reg cells, leading to peptide-MHC specific cells that induced the long-term survival of fully MHC-mismatched (MHC class I and MHC class II) BALB/c heart grafts in immunocompetent B6 mice 130 . In another study, T reg cells from chicken ovalbumin (OVA) antigen-specific, OT-II, transgenic mice, suppressed the in vitro proliferation of T eff cells on stimulation with DCs presenting the relevant OVA peptide. Moreover, in an in vivo model of rheumatoid arthritis, redirected T reg cells from the same OT-II mice homed to the inflamed joint (following an intra-articular injection of OVA in the knee), reduced the number of T H 17 cells in the draining lymph node and decreased inflammation and bone damage 131 .
To date, several TCRs have been successfully used to redirect the specificity of human T reg cells while preserving their in vitro suppressive function. Target antigens include insulin, glutamic acid decarboxylase and factor VIII 23, 45, 46 . T reg cells transduced with a high-affinity TCR have superior suppressive function compared with T reg cells transduced with a low-affinity TCR specific for the same peptide 23 . Strikingly, T reg cells transduced with a high-avidity HLA-A2-restricted tyrosinase-specific TCR from CD8 + T cells recognized an MHC class I-presented antigen while maintaining their capacity to suppress T eff cell responses against that same antigen 47 . This result suggests that TCRs for translational applications using T reg cells can be obtained from cells other than T reg cells or conventional CD4 + T cells.
Chimeric TCRs. TCRs are complex to engineer, in part owing to their heterodimeric nature; introduced subunits can recombine with the endogenous TCRα or TCRβ chain. This complexity raises the risk of generating TCRs with unknown specificities and off-target effects. Several strategies have been devised to address this problem. One approach is to insert extra cysteine residues in the constant region of engineered TCRα and TCRβ chains to form a disulfide bridge between the two to promote preferential pairing of the transduced TCR 132, 133 . 
Complementaritydetermining regions
Parts of the variable chain of the T cell receptor or of an antibody that determine specificity to their cognate antigen.
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Another strategy is to replace the human constant region in TCR chains with a mouse constant region, as interspecies pairing between a murine TCR chain and a human TCR chain has never been observed. This approach also facilitates signal transduction, as the mouse constant region has higher affinity for the TCR-CD3 complex than its human counterpart. Building on this approach to avoid xenogeneic immunogenicity, two independent groups systematically identified the minimum set of residues in the murine TCR constant chains required to 'murinize' the human TCR constant chain. The resulting transgenic TCR had enhanced stability and avidity 134, 135 . A final strategy is to use vectors with strong promoters to express the engineered TCR 136 . Currently, the most promising approach to prevent mixed TCR dimer formation is to use genome editing to engineer the endogenous TCR locus. One or both endogenous TCR chains could be knocked out before a new antigen receptor is introduced 137 . A more elegant method, however, would be to replace the endogenous TCR with the new TCR by knocking it into the TCRα constant region locus (TRAC), ablating expression of the native TCR and endowing the new TCR with the same genomic location and transcriptional regulation as the endogenous gene. Indeed, this was accomplished with reasonable efficiency in primary human T cells by CRISPR-Cas9-mediated editing coupled with a double-stranded DNA template coding for a tumour antigen (NY-ESO)-specific TCR for homology-directed repair 138 .
An additional challenge inherent in engineering TCRs is that they require costimulation to fully activate downstream signalling. To overcome this issue, two groups have generated chimeric TCRs. One group linked a melanoma antigen-specific TCR to the transmembrane and intracellular portions of CD28 followed by CD3ε, observing enhanced expression of TCR at the cell surface, the formation of immune synapses, IL-2 secretion, survival of the engineered T cell and tumour clearance 139 . Another group fused a soluble TCR to a CAR transmembrane and signalling domain, demonstrating that this TCR-CAR was functional in primary T cells and in an NK cell line 140 .
Engineered CAR T reg cells Overview of early CAR T reg cell milestones.
Next-gener ation T reg cell therapy will undoubtedly benefit from the field of immuno-oncology, in particular CAR T cell therapy. Since 2017, when the FDA approved CD19 CAR T cell therapy for paediatric acute lymphoblastic leukaemia and non-Hodgkin lymphoma, there have been 241 CAR T cell therapy clinical trials worldwide (91 in the United States; 14 in Europe, 128 in China, 3 in Canada, 2 in Japan; 2 in Australia and New Zealand, and 1 in Israel) as listed in ClinicalTrials.gov as of January 2018 (ref. 141 ). The first clinical trial using CAR T cells targeted the GP120 region of the HIV envelope glycoprotein and was completed 2 years before CD19 CAR T cells were reported to eradicate tumours in animal models 142 . The GP120 CAR consisted of the CD4 co-receptor (which binds HIV GP120) fused to CD3ζ 143, 144 . However, although HIV-specific cytotoxicity was shown in vitro, GP120 CAR T cell therapy failed to reduce viral load in patients with HIV infection 145 .
As mentioned earlier, robust T cell activation requires the interaction of the TCR with its cognate antigen and the binding of a costimulatory receptor (such as CD28) to its ligand (such as CD80 or CD86) on the surface of an APC. First-generation CARs contained solely a TCR CD3ζ endodomain, which, despite being able to induce T cell activation, could not drive robust T cell expansion 146 . Including the CD28 signalling domain in secondgeneration CARs allowed sustained CAR T cell expansion on repeated exposure to antigen, and these CARs displayed superior cytolytic function 142 . Incorporating an additional costimulatory domain (whether it be 4-1BB (also known as CD137), OX40 or another costimulatory domain) into a CD28-CD3ζ CAR creates a thirdgeneration CAR (containing two costimulatory domains, as opposed to only one in second-generation CARs), further fine-tuning CAR signalling; addition of the intracellular domain of 4-1BB minimizes CAR-induced exhaustion 147, 148 , and including the intracellular domain of OX40 (a costimulatory molecule belonging to the TNF receptor family) decreases CAR-induced IL-10 secretion, limiting the inhibition of antitumour activity 149 .
Engineering murine CAR T reg cells. The first described efforts to engineer T reg cell specificity involved creating a transgenic mouse line expressing an artificial chimeric receptor comprising an extracellular peptide-bound MHC complex linked to an intracellular TCR ζ-chain signalling domain 49 . The peptide antigen chosen was MBP [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] , an autoantigen derived from myelin basic protein (MBP) that induces experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. This receptor design allowed CD4 + CD25 + T reg cells to directly recognize and be activated by the TCR of pathogenic self-reactive T cells 49 . Upon activation by MBP 89-101 -reactive T cells, these engineered T reg cells secreted high levels of anti-inflammatory IL-10 and TGFβ and low levels of proinflammatory IFNγ, consistent with a regulatory function. Moreover, the level of cytokines produced in response to anti-CD3ε or MBP 89-101 -reactive T cell-mediated activation were similar, indicating that the chimeric receptor mimics physiological TCR signalling 49 . Strikingly, adoptive transfer of engineered T reg cells not only prevented MBP 89-101induced EAE but also treated it when performed 11 days or even 31 days (after epitope spreading) following disease induction in an example of bystander suppression 49 . Subsequent work revealed that these T reg cells expressing chimeric receptors functioned primarily by inducing MBP-specific T cells to produce IL-10. The adoptive transfer of non-transgenic MBP-specific T cells from mice treated with engineered T reg cells could prevent MBP 89-101 -induced EAE in naive mice, indicating that pathogenic T cells differentiated into antigen-specific T reg cells in an example of infectious tolerance 150 .
A different chimeric receptor design emerged a few years later in 2009, aimed at engineering T reg cells to prevent colitis 151 . Intrarectal administration of 2,4,6trinitrobenzenesulfonic acid (TNBS) is a common strategy to induce colitis in mice. Ethanol disrupts the intestinal barrier, allowing TNBS to interact with proteins and render them immunogenic, generating the hapten 2,4,6-trinitrophenyl (TNP). The study authors created a tripartite chimeric receptor in which a recognition unit (an antibody single-chain variable fragment (scFv) specific for the hapten TNP) was fused to the transmembrane and cytoplasmic domains of CD28 and to the signalling domain of Fc receptor-γ. Unlike the aforementioned work, this approach allowed T reg cells to directly recognize a disease-specific tissue antigen. TNBS-induced colitis resulted in only 10% mortality in transgenic mice expressing the receptor in T cells, compared with 50% mortality in control mice. Moreover, T reg cells expressing the chimeric receptor were activated specifically by TNPylated cells and suppressed T eff cell proliferation in vitro. When adoptively transferred into wild-type mice 16 h after colitis induction, transgenic T reg cells migrated to the site of colonic damage and prevented colitis. Even though transgenic T reg cells could suppress colitis induced only by TNBS, indicative of their antigen specificity, they could also ameliorate colitis induced by other agents when trace amounts of TNBS were present, which is a hallmark of bystander suppression 152 . Of note, mice treated with transgenic T reg cells also displayed increased survival after a second round of TNBS-induced colitis (25% mortality compared with 66% mortality in controls). Whether this phenomenon was due to persistence of the modified cells or infectious tolerance was not explored 151 .
These initial chimeric receptor designs gave way to the next generation CARs first used in T eff cells for cancer therapy, with two groups generating CD28-CD3ζ CAR T reg cells specific for carcinoembryonic antigen (CEA) 153, 154 . CEA expression is upregulated in benign colon inflammation (ulcerative colitis), as well as in colon cancer in humans 155 , and the first report focused on induced colitis 153 . Similarly to the TNP-specific modified T reg cells developed by the same group 151, 152 , CEA CAR T reg cells localized to the colon, suppressed the production of inflammatory cytokines and prevented T cell-mediated colitis in mice when coadministered with CEA CAR CD4 + T eff cells 153 . As CEA is expressed in the lungs as well as the intestine, the second group tested the function of CEA CAR T reg cells in asthma 154 .
Using a transgenic mouse model in which the human CEA gene promoter drives CEA expression in the pulmonary and gastrointestinal epithelium, the study authors induced allergic airway inflammation via immun ization with OVA. CEA CAR T reg cells potently secreted IL-10 and suppressed T eff cell proliferation in vitro, and localized to the lung on intravenous administration into CEA transgenic mice. Moreover, administration of CEA CAR T reg cells 1 week after initial sensitization, followed by four consecutive days of challenge with OVA, almost completely prevented airway hyper-reactivity and reduced mucus production, eosinophil lung infiltration and the production of T H 2 cell-type cytokines 154 .
Engineering human CAR T reg cells. These encouraging results in mouse disease models moved the field to work in human cells. The first study using a CAR to redirect human T reg cells also involved CEA. However, instead of preventing or alleviating disease in the intestine or the lung, human CEA CAR T reg cell-mediated suppression in vivo was demonstrated via partial protection of a CEA-expressing tumour from CEA CAR T cell-mediated death in immunodeficient mice 156 . One immediate caveat of this setting was that both CAR T reg cells and CAR T cells, which were administered at a 1:1 ratio, targeted the same antigen 156 . Thus, the observed partial protection could have been due to competition between these cell types for antigen rather than due to true suppression. Shortly afterwards, a different group generated human CD19 CAR T reg cells that suppressed the proliferation and cytotoxic activity of CD19 CAR T eff cells in vitro and migrated to CD19-expressing B cell-derived tumours in mice, preventing CD19 CAR T eff cell-mediated tumour killing in vivo at a ratio as low as one CAR T reg cell per 16 CAR T eff cells 157 .
The most immediate application of CAR T reg cells is poised to be in GvHD and organ transplant rejection. Unlike in most autoimmune disorders, there are very clear targets in transplantation in the form of HLA molecules. Moreover, CARs remove the need to activate recipient T reg cells with donor-derived APCs 158 . In 2016, the first HLA-A2 CAR T reg cells were reported; as HLA-A2 is present in 50% of the population, creating tolerance for this allele is advantageous. The study authors demonstrated that HLA-A2 CAR T reg cells suppress T eff cell proliferation and prevent HLA-A2 + PBMC-mediated GvHD in immunodeficient NSG mice. HLA-A2 CAR T reg cells did not kill HLA-A2 + cells in short-term in vitro assays but completely prevented HLA-A2 + PBMC engraftment, leaving open the possibility that they might kill HLA-A2 + cells in vivo 48 . Two subsequent studies also generated HLA-A2 CAR T reg cells 159, 160 and introduced new models to test HLA-A2 CAR T reg cells in vivo. One group demonstrated that HLA-A2 CAR T reg cells suppressed a mixed lymphocyte reaction between HLA-A2 + and HLA-A2 -PBMCs in vivo, reducing ear swelling and preserving HLA-A2 + cells in mice. Of note, this result was accomplished at an HLA-A2 CAR T reg cell to HLA-A2 + PBMC ratio of 1:10, indicating that CAR-mediated suppression of GvHD is similar in potency to TCR-mediated suppression of GvHD 161 . Moreover, HLA-A2 CAR T reg cells prevented the rejection of HLA-A2 + skin grafts by HLA-2 -PBMCs 159 . The other group also used HLA-A2 + skin graft rejection as a model, and found that HLA-A2 CAR T reg cells reduced alloimmune damage, as assessed by a reduction in the number of keratinocytes in the graft and increased blood vessel integrity 160 . Recently, a panel of fully humanized HLA-A2 CARs was generated and tested in T reg cells. Several humanized HLA-A2 CAR T reg cells rapidly migrated to, and persisted in, HLA-A2 + skin grafts, delaying HLA-A2 skin graft rejection 162 .
Introducing B cell-targeting antibody receptor T reg cells.
New applications for CAR T reg cells are still emerging. B celltargeting antibody receptor (BAR) T reg cells have been described recently. Human factor VIII (FVIII) injections are used to treat patients with haemophilia A. Over time, anti-FVIII neutralizing antibodies develop, causing morbidity and death 163 . A BAR containing an immunodominant domain of FVIII, either A2 or C2, as the extracellular www.nature.com/nrd domain, was designed to target FVIII-specific B cells; the intracellular signalling domain remained as CD28-CD3ζ as in a previous FVIII CAR design by the same group 164 . Strikingly, in vitro, human BAR T reg cells displaying either the A2 domain or the C2 domain suppressed antibody production by splenocytes isolated from mice that had been immunized with recombinant FVIII. Furthermore, intravenous administration of human FVIII BAR T reg cells into mice the day before immunization with recombinant FVIII prevented anti-FVIII antibody formation in vivo, whereas infusion of the cells into mice already producing anti-FVIII antibodies decreased antibody titres. BAR T reg cells could thus suppress antibody production even in a xenogeneic setting, both in vitro and in vivo. Whether these cells prevented T follicular helper cells from helping B cells, directly targeted FVIII-specific memory B cells or interacted with APCs to indirectly affect B cells was unclear. To address these questions, T cells and B cells were isolated from mice immunized with FVIII and treated with either BAR T reg cells or control OVA BAR T reg cells. B cells isolated from mice treated with control T reg cells produced anti-FVIII antibodies regardless of the source of the T cells, whereas B cells from mice treated with FVIII BAR T reg cells did not. BAR T reg cells are thus likely to act directly on B cells, either by suppressing them or by killing them 165 .
Alternative targets for CAR T reg cells. CAR T reg cell targets
need not be present on the cell membrane. Our laboratories generated a CAR specific for citrullinated vimentin, a modified protein unique to the inflamed joints of more than 50% of patients with rheumatoid arthritis 166 . Citrullinated vimentin CAR T reg cells recognized and were activated by citrullinated vimentin present in synovial fluid from patients with rheumatoid arthritis; this approach may provide a strategy to restore homeostasis at the site of inflammation 167 . Currently, citrullinated autoantigens are thought to be present in the extracellular milieu primarily as a result of neutrophil extracellular trap (NET)-associated cell death (NETosis). A unique form of programmed cell death, NETosis involves intracellular content extrusion, particularly of genomic DNA-rich NETs of neutrophils infiltrated in synovial tissue 168 .
Adapting CAR signalling for T reg cells. Early experiments
in the field found that incorporating CD28 signalling into CD19 CAR T cells, by switching from CD3ζ alone to a bipartite CD28-CD3ζ intracellular domain, made these CAR T cells resistant to T reg cell-mediated suppression, resulting in higher proliferation of CAR T cells and increased CAR T cell-mediated killing of B cell-derived leukaemia cells 169 . Yet, subsequent experiments reported that CEA CAR T cells containing a CD28-CD3ζ intracellular domain were more susceptible to T reg cells in a solid tumour compared with CAR T cells containing CD3ζ only. Deleting the binding site for the tyrosine-protein kinase LCK on the CD28 moiety of the CEA CAR ablated IL-2 secretion while supporting CAR T cell proliferation and preventing suppression by tumour-infiltrating T reg cells 170 . The seemingly contradictory results of the two studies might reflect how CAR T cells interact with liquid tumours that express CD80 and CD86 (CD19 CAR for B cell-derived leukaemia) and with solid tumours that do not (CEA CAR for non-blood cancer).
Efforts have been made to find the ideal CAR signalling architecture for CAR T cells by comparing how different costimulatory domains induce CAR T cell proliferation and longevity, as well as their ability to secrete specific cytokines and to kill tumour cells (reviewed elsewhere 171 ). However, this is not the case for CAR T reg cells. After the first chimeric receptor design for T reg cells, in which CD3ζ alone was used as a signalling moiety 49 , subsequent CAR T reg cell studies in mice and humans used the prototypical CD28-CD3ζ CAR, with the exception of the use of CD3ζ alone in CD19 CAR T reg cells 157 . Yet, different CAR signalling modalities are now being tested in human T reg cells. One group constructed a CAR recognizing dextran and tested the function of different signalling domains in it using 4-1BB expression as a marker of T reg cell activation 172 . Curiously, 4-1BB-CD3ζ CARs and OX40-CD3ζ CARs induced CAR T reg cell activation, whereas CD28-CD3ζ CARs and CARs containing other signalling architectures did not 172 . This observation is at odds with results obtained with a 'universal' CAR (in which the scFv binds to a targeting module, which in turn recognizes a target antigen) featuring CD3ζ, CD28-CD3ζ or 4-1BB-CD3ζ as a signalling domain 173 . All three CAR T reg cell populations suppressed T eff cell proliferation with the same efficiency and were not cytotoxic in vitro. However, CD28-CD3ζ CAR T reg cells uniquely secreted detectable IFNγ and TNF and were activated to a greater extent than 4-1BB-CD3ζ CAR T reg cells, as assessed by expression of the CD69 early T cell activation marker. 4-1BB-CD3ζ CAR T reg cells efficiently protected a tumour from CAR T cell-mediated killing in a humanized mouse model 173 . In contrast, a study by a different group found that 4-1BB-CD3ζ CAR T reg cells are poor suppressors of T eff cells in vitro and fail to protect skin xenografts in vivo, whereas CD3ζ CAR T reg cells and CD28-CD3ζ CAR T reg cells performed well in both assays. All three CARs activated T reg cells to the same extent, as assessed by their upregulation of CD69 expression 174 . The discrepancies observed in these preliminary studies may be due to the use of different experimental models and also to the different activation markers used; the levels of 4-1BB, the activation marker used in the first study 172 , may be more sensitive to activation downstream of TNF receptor family members than the levels of CD69, which was the activation marker used in the second and third studies 173, 174 . Current work in our laboratories focuses on systematically studying the impact of different signalling domains on CAR T reg cell and CAR T eff cell survival, stability and function 175 . From a clinical standpoint, it would be valuable to develop a CAR that maximizes the properties of T reg cells and is simultaneously a poor inducer of cytotoxic and proinflammatory responses even if it is inserted in a T eff cell; such responses could contaminate T reg cell preparations and thus jeopardize the efficacy and safety of CAR T reg cell therapy.
Finally, the choice of scFv binding domain may also impact CAR signalling as varying the affinity of scFv modulates CAR T cell function 176 . Work comparing a CD19 CAR with a GD2 CAR (GD2 is a disialoganglioside expressed in neuroblastomas) found that the latter is substantially more prone to aggregation, tonic signalling and subsequent T cell exhaustion than the former 147 . Thus, tailored signalling architectures may be required to accommodate differences in the affinity of, and the propensity for self-aggregation amongst, scFv chains. Indeed, 4-1BB costimulation was superior to CD28 costimulation in diminishing GD2 CAR tonic signallinginduced exhaustion 147 . Curiously, in the studies discussed above, CEA CD28-CD3ζ CAR T reg cells were used to suppress CEA CD28-CD3ζ CAR T cells 156 , whereas CD19 CD3ζ CAR T reg cells were used to suppress CD19 CD28-CD3ζ CAR T eff cells in a different study 157 . The rationale behind using different CAR signalling domains for the same scFv in T reg cells and T eff cells in the second article was not given. Intriguingly, T reg cells expressing only anti-HLA-A2 scFv migrated to and protected an HLA-A2 + skin graft in NSG mice to the same extent as CD28-CD3ζ HLA-A2 CAR T reg cells, possibly indicating the occurrence of bystander suppression via polyclonal endogenous TCR signalling 160 . Whether CAR-mediated signalling is always required for T reg cell function, whether there is an ideal signalling architecture for CAR T reg cells and whether such a signalling architecture is dependent on a specific scFv require further investigation.
Next-generation T reg cell engineering Synthetic biology
Developing T reg cells as living drugs for autoimmune diseases need not be limited to use of TCRs and CARs. Synthetic immunology has produced a number of artificial receptors and systems that warrant testing in T reg cells. These systems include a T cell antigen coupler that recruits the endogenous TCR complex to a non-MHC target via a linked scFv 177 , CARs optimized to bind and be activated by soluble ligands 178 , and a split, universal and programmable (SUPRA) CAR system that fine-tunes the strength of T cell activation 179 . CAR variants may be indispensable in some of these systems. For instance, the SUPRA CAR system encompasses a receptor that recognizes multiple targets and is activated only if all of the targets are present. This feature is especially important when one is targeting tissue-specific antigens and solid tumours, as discovering a single antigen that is uniquely expressed in that tissue is highly unlikely. Another hurdle to optimal CAR function is tonic signalling and concomitant exhaustion. Synthetic Notch is a gene circuit in which binding to one target elicits translocation of an engineered Notch transcription factor into the nucleus, which in turn activates the transcription of a CAR receptor that recognizes a different antigen 180 . This system thus allows for greater specificity, by requiring two distinct antigens to elicit T cell activation, and prevents tonic signalling and undesired binding to CAR by only expressing CAR if the first antigen is recognized.
Rewiring cytokine signalling
Not surprisingly, cytokines play a key part in the outcome of an immune response. T reg cells constitutively express CD25, the high-affinity chain of the IL-2 receptor, effectively depriving T eff cells of IL-2. With this fact in mind, T reg cells have been used to deprive T eff cells of additional cytokines by expressing chimeric highaffinity cytokine receptors in engineered T reg cells. Use of receptors in which the extracellular domain of one cytokine receptor is fused to the intracellular domain of a different receptor prevents the corresponding proinflammatory cytokine from having biological efficacy. This strategy successfully converted IL-4 signalling, which limits T cell persistence and effector function in the tumour microenvironment, into IL-7 signalling, augmenting antitumour activity 181 . Converting proinflammatory cytokine signalling into IL-2 or IL-10 signalling in engineered T reg cells could increase the suppression of inflammation 182 . Indeed, designer cells that could sense TNF and IL-22, which in turn elicited secretion of IL-4 and IL-10, resolved local inflammation in a mouse model of psoriasis 183 . Ultimately, T reg cells could incorporate entire synthetic gene circuits that secrete anti-inflammatory cytokines in response to proinflammatory cytokines, effectively remodelling the cytokine milieu.
Genome editing
Genome editing, which uses engineered DNA endonucleases programmed to recognize and bind to a specific site in the genome, allows genomes to be precisely modified and holds promise in next-generation cell therapy. The past two decades have witnessed the development of several generations of engineered nucleases that offer great opportunities for gene therapy, including zinc-finger nucleases and transcription activatorlike effector nucleases, although these technologies are laborious to implement. The field changed dramatically with the advent of CRISPR as a tool to edit the genome of human cells 184 . The CRISPR-Cas9 system includes the Cas9 nuclease, which induces double-stranded DNA breaks at specific locations in the genome; Cas9 is directed to target locations by a single guide RNA, which can be designed to interact with any 20-base-pair (bp) DNA sequence upstream of an NGG (where N is any nucleo base and G is guanine) protospacer-associated motif through Watson-Crick base pairing. These properties make CRISPR-Cas9 the cheapest, most efficient and most scalable genome editing technology to date.
Since the first demonstration that genes in primary human T cells could be edited with use of CRISPR-Cas9 (ref. 185 ), tremendous progress has been made in our capacity to perform CRISPR-mediated gene modifications in human T cells; the achievements include biallelic gene knockout with efficiencies greater than 80% 186 , for example, of the TRAC locus, and the knock-in of multiple genes at precise genomic locations in primary human T cells 138 . This progress has been achieved in part by improved delivery methods; electroporation of Cas9 protein complexed with guide RNA (ribonucleoprotein (RNP)) is the delivery method of choice for T cells.
Several preclinical studies using CRISPR-Cas9 to disrupt genes in human T cells have been published. These include knocking out the gene encoding C-C chemokine receptor type 5 (CCR5) in CD4 + T cells, which generated T cells that were resistant to HIV infection 185 ; knocking out the gene encoding CD7 in CD7 CAR T cells, which prevented fratricide, as T cells themselves express
Tonic signalling
Low level of signalling independent of activating antigen in resting T cells.
www.nature.com/nrd CD7 (ref. 187 ); knocking out the gene encoding programmed cell death protein 1 (PD1) in CD19 CAR T cells, which improved tumour clearance in a humanized mouse model 188 ; and a step towards the generation of 'universal' exhaustion-resistant CAR T cells by ablation of the genes encoding β 2 -microglobulin, TCR and PD1 (ref. 189 ). Clinical trials using CRISPR technology in the United States started recently. The first CRISPR clinical trial in the United States, launched by CRISPR Therapeutics and Vertex, is treating patients with the blood disorder β-thalassaemia (NCT03655678) (see Related links). The first T cell cancer immunotherapy trial is being conducted by the University of Pennsylvania in partnership with Tmunity and the Parker Institute for Cancer Immunotherapy (NCT03399448). These studies have proceeded despite recent reports that CRISPR-Cas9 editing can provoke large genomic deletions and rearrange ments away from the target site 190 . Efforts towards engineering high-fidelity versions of Cas9 and alternative CRISPR-Cas systems are under way. Of note, CRISPR-mediated editing is not limited to altering genomic sequence; new CRISPR-Cas systems and its variants have been engineered for targeted DNA methylation, gene activation and direct RNA editing [191] [192] [193] .
Improving delivery
Currently, the manufacture of CAR T cells uses retroviral and lentiviral transduction to deliver and integrate genetic material into T cells (fIG. 5) . Lentiviruses, which are members of the retrovirus family, have a diploid RNA genome. Safe use of such viruses is achieved by splitting the three main coding regions of the genomegag (encoding structural proteins), pol (encoding reverse transcriptases and integrases) and env (encoding virus envelopes) -into separate packaging plasmids that are combined only during the transfection process for viral production. This strategy allows the gene of interest, flanked by long terminal repeat sequences, to be integrated into the genome of T cells while prohibiting viral replication 194 . Despite progress in the use of lentiviruses to genetically modify T cells, this approach features several drawbacks, including the random integration of the gene of interest, a different number of gene copies per cell and the use of a constitutive and strong promoter to drive gene expression, resulting in non-physiological gene regulation. Indeed, CAR expression levels in cells transduced by lentiviruses differ between patients and are often supraphysiological, prompting CAR T cell exhaustion 195 Fig. 5 | Methods for delivering genetic material to engineer regulatory T cells. a | The first FDA-approved method for delivering genetic material to engineer regulatory T cells uses retroviruses or lentiviruses, which are pseudodiploid singlestranded RNA viruses. Genomic integration of the gene cassette of interest is random, resulting in non-physiological gene regulation with often multiple copies of the gene per cell. The second FDA-approved method uses recombinant adenoassociated viruses (AAVs); these viruses persist inside the cell as a double-stranded DNA episome that is not integrated into the genome and will therefore be diluted over time in replicating cells. Many groups combine use of recombinant AAVs with use of CRISPR-based technologies, as the episome can serve as a homology repair (HR) template, an approach recently approved by the FDA for clinical trials. b | A third method, which is purely non-viral but not FDA approved yet, electroporates the desired cassette as double-stranded DNA or an ultramer (single-stranded DNA) template together with a Cas9-ribonucleoprotein (RNP) complex. Although this method leads to a single copy of the gene being precisely integrated at a desired location in the genome, it also typically results in lower modification efficiencies.
NATuRe RevIews | DRug DisCoveRy by means of CRISPR-Cas9 normalized CAR expression between patients, averted tonic CAR signalling and allowed the internalization and re-expression of the CAR on the cell surface upon CD19 recognition, mimicking the surface expression dynamics of physiological TCR 195 .
In the study that inserted the CAR into the TRAC locus 195 , recombinant AAV (rAAV) was used to deliver the CAR DNA homology repair template into the T cells (fIG. 5) . AAVs are single-stranded linear DNA viruses that can be safely produced, similarly to lentiviruses, by splitting the main coding regions -rep (encoding replication proteins), cap (encoding capsid proteins) and aap (encoding assembly proteins) -into separate packaging plasmids during transfection for virus production. In contrast to lentiviruses, however, after transduction, the inverted terminal repeat-flanked transgene of the rAAV persists inside the cell as an episome rather than being integrated into the genome 196 (fIG. 5) . rAAV is therefore lost over time in replicating cells, making it ideal to deliver a homology repair template to introduce specific mutations or knock in a gene cassette of interest.
There are nine serotypes of rAAV (rAAV1-rAAV9), each of which has a different tropism. Currently, rAAV6 is the most efficient serotype for T cell transduction 138, 197 . Several groups are working on bioengineering the rAAV capsid via multiplexed sequential directed evolution screens using capsid libraries with the goal of making rAAVs with novel cell specificities 198, 199 . Thus, in the future, specific rAAVs could be made to selectively target distinct T cell (or even T reg cell) subtypes, vastly improving the precision and safety of gene editing for T cell therapy.
A non-viral approach to knock in DNA sequences more than 1 kilobase (kb) long at a specific genomic site in human T cells has also been reported 138 (fIG. 5 ). Contrary to expectation, double-stranded DNA templates were not toxic when co-electroporated with CRISPR RNPs. This method corrected a pathogenic CD25 mutation in cells from patients with a monogenic autoimmune disease, inserted GFP downstream of several genes and inserted a transgenic TCR into the TRAC locus of T eff cells, demonstrating its potential 138 . This approach holds great promise, as manufacturing and testing clinical grade lentivirus or rAAV is timeconsuming, expensive and plagued by safety issues. However, this approach is limited by the fact that editing efficiency decreases as the size of DNA templates increases, limiting the electroporated construct to an ~1.5-kb insert, which includes two homology arms of 300 bp long. CAR and TCR constructs are ~1.5 kb long and may therefore be too large to be efficiently integrated into DNA by this method; a GFP tag, by contrast, is only 750 bp long. Single-stranded rAAV6 templates have a packaging capacity of 4.7 kb, leaving up to 3.6 kb available for the gene construct after exclusion of the homology arms and inverted terminal repeat regions 200 . In conclusion, the methods used for gene editing differ depending on cell type, the insert size and the editing efficiency required. Furthermore, viral approaches can be combined with CRISPR RNP complexes to disrupt genes and/or to insert new cassettes, such as CAR or TCR transgenes.
Designer T reg cells CRISPR-Cas9 genome editing could potentially knock in antigen receptors in precise genomic locations while simultaneously editing multiple genes that regulate T reg cell function (fIG. 2) . As discussed earlier, one hurdle facing T reg cell therapy is ensuring the survival of the cells following infusion. Deleting the gene encoding JUN amino-terminal kinase 1 (JNK1) in murine T reg cells was shown to make them resistant to apoptosis, and JNK1deficient T reg cells secreted higher levels of IL-10 and TGFβ and protected transplanted islets from rejection 100 days longer than their wild type counterparts 201 . Additionally, T reg cells can become unstable and transdifferentiate into pathogenic T H 17 cells in inflammatory milieus 4 . PKCθ, the most abundant PKC isoform in T cells, is activated downstream of TCR and CD28, resulting in the induction of nuclear factor of activated T cells and nuclear factor-κB. Deletion of PRKCQ, which codes for PKCθ, or pharmacological inhibition of PKCθ reduced the propensity of T reg cells to differentiate to T H 17 cells while preserving the suppressive function of T reg cells in mice and humans 39, 40 . A complementary strategy could involve stabilizing high FOXP3 levels. T reg cells can have diminished levels, or even loss, of FOXP3 expression as a result of increased methylation of the TSDR locus over prolonged periods of in vitro culture 202 , or because of the CHIP-dependent ubiquitylation of FOXP3 in response to proinflammatory cytokines 41 . Indeed, genetically ablating STUB1 (the gene encoding CHIP) in murine T reg cells prevented FOXP3 degradation, whereas STUB1 overexpression abrogated T reg cell function in vitro and in vivo 41 . DBC1 also promotes FOXP3 destabilization by associating with FOXP3 to trigger its degradation in response to TNF by activating caspase 8. Accordingly, T reg cells in DBC1-deficient mice were present in larger numbers, and were more potent suppressors of EAE and colitis upon adoptive transfer, than T reg cells from wild-type mice 42 . Several other proteins interact with FOXP3 (ref. 203 ), and the list continues to grow. Future mechanistic studies are likely to yield additional targets for modulating FOXP3 stability. Finally, an alternative approach would be to enforce the expression of factors shown to preserve T reg cell identity. One example is BACH2, a transcriptional repressor that reduces the differentiation of naive T cells into T H 1, T H 2 and T H 17 cells 38 . Another example is STAT5-CA, a constitutively active form of signal transducer and activator of transcription 5, a key molecule that is activated downstream of IL-2 signalling and is essential for the suppressive function of T reg cells 204 .
As well as optimizing the suppressive properties of T reg cells, genome editing could be used to tailor T reg cells to different needs. In particular, there is growing evidence that T reg cells have an important role in tissue repair by producing amphiregulin and keratinocyte growth factor, amongst other molecules 205, 206 . Including these and other factors in engineered T reg cells can further increase their therapeutic value. Finally, the recent generation of hypoimmunogenic human pluripotent stem cells via genome editing 207, 208 , coupled with ongoing efforts to differentiate stem cells into T reg cells 209 , could revolutionize engineered T reg cell therapy.
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Conclusion Improper immune reactivity and inflammation underlie many currently incurable diseases. Using synthetic bio logy to fine-tune and augment the properties of immune cells will accelerate the implementation of curative cellbased therapies for autoimmunity and, ultimately, help achieve one of the most elusive goals in immunology: immune tolerance.
Currently, T reg cell manufacturing is still not ideal, largely due to the lack of tailored instruments and reagents. A process that combines MACS with FACS would allow the bulk processing and precision isolation of highly pure T reg cells as a starting material for manufacturing. The low proliferation rates of T reg cells in vitro are in sharp contrast to their highly proliferative state in vivo [210] [211] [212] , suggesting that poor proliferation is not an intrinsic characteristic of human T reg cells but likely a result of the suboptimal conditions currently used to expand T reg cells. Culture media, growth factors and stimulants that are suited for T reg cell biology and that can accommodate donor variability are yet to be developed. Moreover, current T reg cell manufacturing processes are costly and labour-intensive. Maximizing automation will not only decrease costs but will also improve reproducibility and lead to standardization.
It is the right time to design therapies using T reg cells. Recent decades have witnessed dramatic progress in our knowledge of basic T reg cell biology and autoimmune diseases, and also in our capacity to build artificial immune receptors and edit the genome of primary immune cells. However, many questions remain in the field of T reg cell biology and T reg cell therapy. For example, it will be important to identify markers that can distinguish lineage-committed thymic T reg cells from peripheral T reg cells and to determine whether certain T reg cell subsets are more suited to engineering for T reg cell therapy than others. Indeed, it is currently unclear whether the plasticity of T reg cells reflects the initial heterogeneity of a T reg cell population and whether only a subset of T reg cells (or all T reg cells) can become T eff cells. The origin of T reg cells that control local inflammation (that is, whether they are tissue resident or circulating) also needs to be determined. Moving into the clinic, a better understanding of how T reg cells maintain tissue integrity during homeostasis and in autoimmunity and organ transplantation, whether (and how) T reg cells change their identity in autoimmunity and whether T reg cells from patients with autoimmune disease are intrinsically defective, and thus unsuitable for therapeutic use, will also be critical.
To optimize T reg cell engineering, we must ascertain whether there is a minimal set of signalling pathways that, when incorporated into an artificial immune receptor such as a CAR, guarantees the survival, stability and suppressive function of engineered antigen-specific T reg cells. Advancing the field of engineered CAR T reg cell therapy also requires a better understanding of whether the inflamed tissue, the pathogenic T cells causing the immune response or the APCs activating the pathogenic T cells are the best target for engineered T reg cells, and whether the target molecule on these cells can be a soluble antigen instead of a surface molecule.
In the next decade, as some of these outstanding questions are addressed, we can expect to see continued improvements in the manufacture of T reg cells and an increased alliance with synthetic biology and genome editing to tailor T reg cell therapies to a growing number of conditions.
